文献速递肝病

同种异体骨髓来源间充质基质细胞治疗乙型肝炎病毒相关慢加急性肝衰竭:一项随机对照试验

Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial.
PubMed 文献 · Hepatology · 2017-05-27

该开放标签、非盲法随机对照研究纳入110例乙型肝炎病毒相关慢加急性肝衰竭患者,对照组54例仅接受标准内科治疗,试验组56例每周输注同种异体骨髓来源间充质基质细胞、连续4周并随访24周。间充质基质细胞组累积生存率73.2%(95%CI 61.6%-84.8%)高于标准内科治疗组55.6%(95%CI 42.3%-68.9%),P=0.03;严重感染发生率间充质基质细胞组16.1%低于标准内科治疗组33.3%,P=0.04。

要点

  • 同种异体骨髓来源间充质基质细胞组24周累积生存率73.2%,高于标准内科治疗组55.6%(P=0.03)。
  • 间充质基质细胞组严重感染发生率16.1%,低于标准内科治疗组的33.3%(P=0.04)。
  • 多器官衰竭和严重感染所致死亡率标准内科治疗组37.0%高于间充质基质细胞组17.9%(P=0.02)。

核心结论

  • 外周输注同种异体骨髓来源间充质基质细胞对乙型肝炎病毒相关慢加急性肝衰竭患者安全且方便,通过改善肝功能、降低严重感染发生率显著提高24周生存率。

研究设计与样本

  • 2010年至2013年纳入110例乙型肝炎病毒相关慢加急性肝衰竭患者的开放标签、非盲法随机对照研究。
  • 对照组54例仅接受标准内科治疗,试验组56例每周输注1.0至10×10^5个细胞/kg同种异体骨髓来源间充质基质细胞、连续4周,随后随访24周。

主要发现

  • 间充质基质细胞组累积生存率73.2%(95%CI 61.6%-84.8%)高于标准内科治疗组55.6%(95%CI 42.3%-68.9%),P=0.03。
  • 间充质基质细胞组严重感染发生率为16.1%,低于标准内科治疗组的33.3%,P=0.04。
  • 多器官衰竭和严重感染所致死亡率标准内科治疗组为37.0%,高于间充质基质细胞组的17.9%,P=0.02。
  • 与对照组相比,同种异体骨髓来源间充质基质细胞治疗明显改善血清总胆红素和终末期肝病模型评分等临床实验室指标。
  • 未发生输注相关副作用,但随访第5至24周间充质基质细胞组发热较标准内科治疗组更常见;两组均无患者发生癌变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Mortality from hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) is high due to limited treatment options. Preclinical and clinical investigations have proved that treatment with mesenchymal stromal cells (MSCs) is beneficial for recovery from liver injury. We hypothesized that the outcome of HBV-related ACLF would be improved by MSC treatment. From 2010 to 2013, 110 patients with HBV-related ACLF were enrolled in this open-label, nonblinded randomized controlled study. The control group (n = 54) was treated with standard medical therapy (SMT) only. The experimental group (n = 56) was infused weekly for 4 weeks with 1.0 to 10 × 105 cells/kg allogeneic bone marrow-derived MSCs and then followed for 24 weeks. The cumulated survival rate of the MSC group was 73.2% (95% confidence interval 61.6%-84.8%) versus 55.6% (95% confidence interval 42.3%-68.9%) for the SMT group (P = 0.03). There were no infusion-related side effects, but fever was more frequent in MSC compared to SMT patients during weeks 5-24 of follow-up. No carcinoma occurred in any trial patient in either group. Compared with the control group, allogeneic bone marrow-derived MSC treatment markedly improved clinical laboratory measurements, including serum total bilirubin and Model for End-Stage Liver Disease scores. The incidence of severe infection in the MSC group was much lower than that in the SMT group (16.1% versus 33.3%, P = 0.04). Mortality from multiple organ failure and severe infection was higher in the SMT group than in the MSC group (37.0% versus 17.9%, P = 0.02). CONCLUSION: Peripheral infusion of allogeneic bone marrow-derived MSCs is safe and convenient for patients with HBV-related ACLF and significantly increases the 24-week survival rate by improving liver function and decreasing the incidence of severe infections. (Hepatology 2017;66:209-219).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lin BL, Chen JF, Qiu WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial. Hepatology. 2017. PMID: 28370357. doi:10.1002/hep.29189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。